Cerivastatin

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C26H34FNO5
Molecular Weight
459.55 g/mol
PubChem CID
446156
Aliases
Baycol, Lipobay

Pharmacological Mechanism

HMG-CoA reductase inhibitor (statin) — withdrawn worldwide 2001-08-08 after 52 confirmed fatal rhabdomyolysis cases, predominantly attributable to coadministration with gemfibrozil. Mechanism of the fatal DDI: CYP2C8 inhibition by gemfibrozil glucuronide raises cerivastatin AUC ~6× (Backman 2002 PMID:12496749 — verbatim AUC 559% of control). Bayer paid $1.15 billion to settle lawsuits over the withdrawal. Retained in the registry for historical reference and as the canonical CYP2C8 DDI cautionary tale. PK (Baycol label + Mück 2000 PMID:10976657 review): Absolute F 60% (range 39–101%) due to presystemic first-pass, Tmax 2–3 h, terminal t½ 2–4 h, plasma protein binding >99%, apparent Vd ~0.3 L/kg (~21 L). Dual CYP2C8/CYP3A4 metabolism — the latter pathway only ~50% effective when both routes are inhibited, which is why gemfibrozil (CYP2C8 inhibitor, AUC ↑5.59× Wave 2a v1.1) and itraconazole (CYP3A4) produced lethal rhabdomyolysis combinations and led to the August 2001 worldwide withdrawal after 52 fatal cases.

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~6.62 µg/L)1×t½ (3h): 50% remaining (~3.31 µg/L)2×t½ (6h): 25% remaining (~1.65 µg/L)3×t½ (9h): 12.5% remaining (~0.827 µg/L)4×t½ (12h): 6.3% remaining (~0.414 µg/L)5×t½ (15h): 3.1% remaining (~0.207 µg/L)
Plasma (PO)t½ Decay (3h)
  • 0×t½0h100% (6.62 µg/L)
  • 1×t½3h50% (3.31 µg/L)
  • 2×t½6h25% (1.65 µg/L)
  • 3×t½9h12.5% (0.827 µg/L)
  • 4×t½12h6.3% (0.414 µg/L)
  • 5×t½15h3.1% (0.207 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)2.36h
Est. Peak (Cmax)6.62 µg/L
Clearance (CL)4.85 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References